EventsMOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed.
Published
This submission belongs to the session 08. REVIEWWWERS.PUB-08, Reviewers & Pre-Post Publication Workshop, Bilbao-Miami, USA, 2022. of the event MOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed.
Published date
16 Dec, 2022
Academic Editor
author-avatarHumbert G. Díaz
Citation
Test Test, Test, in Proceedings of MOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed., 1 January–15 January 2023, MDPI: Basel, Switzerland, doi: 10.3390/mol2net-08-13869
Share
Email
Facebook
Twitter
LinkedIn

Test

image
1. Test Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Abstract

*Note: Mol2Net conference is associated to different MDPI journals special issues guest edited by Mol2Net Conference Committee members. This is an strategy to increase the online post-publication visibility of papers and conference, promote post-publication brainstorming discussion, and increase authors feedback. This association implies that our conference perform post-publication indexing of selected papers already published in MDPI journals with the consent of the issue editors. We publish free-of-cost these post-publication summaries. They include a shortened title, corresponding author info, and paper cover pdf file. The cover pdf file contains paper first page with all authors, abstract, full reference , and link to original papers.

Reference: This is a note for the paper published in the special issue Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering, Edited by: Dr. I.A. Neacsu and Dr. B.S. Vasile, Managing Editor: C. Zha, Visit the link to see original paper. Reference: Pharmaceutics 2022, 14(5), 941; https://doi.org/10.3390/pharmaceutics14050941

Summary:The incidence of type I diabetes has been increasing worldwide at an annual rate of approximately 3%. One of the strategies to treat type I diabetes is islet transplantation, in which damaged β-cells are replaced with new islets. To improve β-cells’ expansion and pseudoislet formation, studies are focusing on using extracellular-matrix-resembling substrates. We evaluated the potential of salmon fibrinogen and chitosan electrospun scaffold as cell substrate for cultivating MIN-6 cells. The morphology of cells, insulin secretion and gene expression was evaluated and compared with other substrates (nanofibrous scaffold, microporous scaffold and tissue culture polystyrene). We found that all tested 3D conditions favored the pseudoislet formation of MIN-6 cells. The insulin secretion of MIN-6 cells after stimulation with high-glucose media shows approximately a 9-fold increase compared to the control group when a fibrinogen/chitosan-based electrospun scaffold was used for cultivation. The differences in insulin secretion were corroborated by differences in gene expression. The differences in insulin secretion could probably be attributed to the differences in the mechanical and/or chemical nature of the tested substrates.

Keywords
Test
Manuscript

Test

Test